Back to press releases

Nyxoah to Participate in Annual Piper Sandler Healthcare Conference

20 th Nov, 2020
, 7h


Mont-Saint-Guibert, Belgium

Nyxoah S.A. (EBR: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, today announces the participation of its management team in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Olivier Taelman, CEO of Nyxoah, will participate in a fireside chat as part of conference. The company will also host 1x1 investor meetings from December 1st until December 3rd. Meetings may be requested exclusively via Piper Sandler.

The pre-recorded fireside chat can be accessed beginning November 23, 2020 by visiting Financial Calendar & Events in the Investor Relations section on the company's website at Nyxoah in the Investor Relations section on the Company's website at An archived replay of this fireside chat will be available for 60 days on the Company's website after the conference.

- ENDS -


Investor and Media Contact:

Milena Venkova
+32 490 11 93 57

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions. Nyxoah’s lead solution is the Genio® system, a CE-Mark validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke.

Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.

For more information, please visit

Caution – CE marked since 2019. Investigational device in the United States. Limited by federal law to investigational use.

1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071–1078.

Discover Genio®

A sleep solution by Nyxoah 

Discover Genio®

All rights reserved © 2020 Nyxoah S.A. All content on this presentation, including the texts, trademarks, service marks, logos, illustrations, photos, graphics, design etc., are the property of Nyxoah SA. Nyxoah S.A. owns all rights with respect to any of their trademarks, service marks, logos, and copyrighted works appearing on this presentation. Patented and design protected technology. Device not for sale in U.S. The Genio® system by Nyxoah is intended to be used for patients who suffer from moderate to severe Obstructive Sleep Apnea (AHI of 15 to 65), have not tolerated, failed or refused PAP therapy and are not significantly overweight. Reviewed and approved: February 2020